WO2004108078A3 - Anticorps conçus de maniere rationnelle - Google Patents

Anticorps conçus de maniere rationnelle Download PDF

Info

Publication number
WO2004108078A3
WO2004108078A3 PCT/US2004/016574 US2004016574W WO2004108078A3 WO 2004108078 A3 WO2004108078 A3 WO 2004108078A3 US 2004016574 W US2004016574 W US 2004016574W WO 2004108078 A3 WO2004108078 A3 WO 2004108078A3
Authority
WO
WIPO (PCT)
Prior art keywords
rationally designed
antibodies
designed antibodies
fragments
fused
Prior art date
Application number
PCT/US2004/016574
Other languages
English (en)
Other versions
WO2004108078A2 (fr
Inventor
Katherine S Bowdish
Shana Frederickson
Mark Renshaw
Cecilia Orencia
Original Assignee
Alexion Pharma Inc
Katherine S Bowdish
Shana Frederickson
Mark Renshaw
Cecilia Orencia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc, Katherine S Bowdish, Shana Frederickson, Mark Renshaw, Cecilia Orencia filed Critical Alexion Pharma Inc
Publication of WO2004108078A2 publication Critical patent/WO2004108078A2/fr
Publication of WO2004108078A3 publication Critical patent/WO2004108078A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des anticorps ou des fragments correspondants comprenant au moins deux régions CDR remplacées par des peptides biologiquement actifs ou fusionnées avec ceux-ci. Les compositions contenant ces anticorps ou des fragments correspondants sont utiles dans des applications thérapeutiques et diagnostiques.
PCT/US2004/016574 2003-06-02 2004-05-26 Anticorps conçus de maniere rationnelle WO2004108078A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45259003A 2003-06-02 2003-06-02
US10/452,590 2003-06-02

Publications (2)

Publication Number Publication Date
WO2004108078A2 WO2004108078A2 (fr) 2004-12-16
WO2004108078A3 true WO2004108078A3 (fr) 2006-04-06

Family

ID=33510369

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/016574 WO2004108078A2 (fr) 2003-06-02 2004-05-26 Anticorps conçus de maniere rationnelle

Country Status (1)

Country Link
WO (1) WO2004108078A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003295623B2 (en) * 2000-12-05 2008-06-05 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
WO2017093947A1 (fr) 2015-12-04 2017-06-08 Novartis Ag Compositions à greffe de cytokine-anticorps et procédés d'utilisation pour l'immunorégulation
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
MX2019014023A (es) 2017-05-24 2020-02-17 Novartis Ag Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer.
GB201711208D0 (en) 2017-07-12 2017-08-23 Iontas Ltd Ion channel inhibitors
JOP20210326A1 (ar) 2019-06-12 2023-01-30 Novartis Ag أجسام مضادة للمستقبل 1 لببتيد إدرار الصوديوم في البول وطرق استخدامها

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018221A1 (fr) * 1993-02-02 1994-08-18 The Scripps Research Institute Procedes de production de sites de liaison de polypeptides
WO1996040750A1 (fr) * 1995-06-07 1996-12-19 Glaxo Group Limited Peptides et composes se fixant a un recepteur de thrombopoietine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018221A1 (fr) * 1993-02-02 1994-08-18 The Scripps Research Institute Procedes de production de sites de liaison de polypeptides
WO1996040750A1 (fr) * 1995-06-07 1996-12-19 Glaxo Group Limited Peptides et composes se fixant a un recepteur de thrombopoietine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BARBAS ET AL: "Human Autoantibody Recognition of DNA.", PROC NATL ACAD SCI USA., vol. 92, March 1995 (1995-03-01), pages 2529 - 2533, XP002927212 *
HELMS ET AL: "Destabilizing Loop Swaps in the CDRs of an Immunoglobulin VL Domain.", PROTEIN SCIENCE., vol. 4, 1995, pages 2073 - 2081, XP002994871 *
MANJUNATHA KINI R ET AL: "A Novel Approach to the Design of Potent Bioactive Peptides by Incorporation of Proline Brackets: Antiplatelet Effects of Arg-Gly-Asp Peptides.", FEBS LETTERS., vol. 375, 1995, pages 15 - 17, XP002994872 *

Also Published As

Publication number Publication date
WO2004108078A2 (fr) 2004-12-16

Similar Documents

Publication Publication Date Title
WO2004050017A3 (fr) Anticorps elabores de maniere rationnelle
WO2005060642A3 (fr) Anticorps conçus rationnellement
WO2002046238A3 (fr) Anticorps conçus de maniere rationnelle
EP1636334A4 (fr) Anticorps anti-cd30 de recombinaison et leurs utilisations
WO2003068801A3 (fr) Variantes d'anticorps a vitesses d'association d'antigene accelerees
WO2003074551A8 (fr) Conjugues d'agents therapeutiques ou cytotoxiques et de peptides bioactifs
IL228034A0 (en) Formulations with a high concentration of antibodies and proteins
SI1623997T1 (sl) Rekombinantno protitelo in fragmenti prepoznajoč gangliozid n-glikolil-gm3 in njih uporaba za diagnozo in zdravljenje tumorjev
HK1109160A1 (en) Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours
AU2002308348A1 (en) Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours
WO2005082004A3 (fr) Anticorps rationnellement concus presentant un squelette a domaine echange
WO2005030793A3 (fr) Anticorps se liant aux cxcr3 humains
WO2004108078A3 (fr) Anticorps conçus de maniere rationnelle
AU2003227148A1 (en) Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer
WO2005009366A3 (fr) Restauration d'une fonction vasculaire
AU2002352170A8 (en) Anti-t cell immunotoxin fusion protein and its therapeutic use
EP1633399A4 (fr) Anticorps recombines, compositions et leurs methodes de fabrication et d'utilisation
WO2001007479A3 (fr) Matieres vivantes et methodes utiles pour le diagnostic ou le traitement de maladies
AU2003210054A1 (en) Anti-rank monoclonal antibodies and pharmaceutical composition containing the same
WO2003106478A3 (fr) Anticorps se liant a l'integrine alphae
WO2002066492A3 (fr) Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques.
WO2005025489A3 (fr) Usage therapeutique de g53135-05 (fgf-20) en protection contre les rayonnements
AU2003211554A1 (en) Protein having osteogenic protein-binding region and gene encoding the same
WO2004005332A3 (fr) Peptides secretes
WO2005003781A3 (fr) Especes de polypeptides secretes associes a des troubles cardiovasculaires

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase